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ABSTRACT  
Introduction: Acute exacerbations of Chronic Obstructive Pulmonary disease 
(AECOPD) due to Pseudomonas aeruginosa (PA) are associated with worse 
outcomes. PA antibiotic resistance is important to determine treatment and may 
influence clinical outcomes. 
Objectives: To study clinical characteristics and outcomes in patients with 
AECOPD associated with PA based on their antibiotic resistance. 
Methods: Prospective observational study including all patients with AECOPD 
and positive PA sputum culture admitted in a Respiratory ward in a tertiary 
hospital in Barcelona during 2013-2014. PA was defined as Resistant (PA-R) 
when the antibiogram showed ≥1 resistance. 
Results: 401 patients with AECOPD were evaluated. Of them, 54 (13 %) had a 
positive PA sputum culture. 82% were men, median age 77 (SD 7) years old 
and FEV1 36 (SD 17) % of predicted.  PA-R was isolated in 35 patients (66%) 
and PA-Sensitive (PA-S) was isolated in 18 (34%) patients. No differences were 
found in demographics, lung function and comorbidities among groups. PA-R 
patients were more likely exposed to prior oral corticosteroids (77% vs. 44%, p 
= 0.03) and antibiotics (77% vs. 31%, p = 0.01), respectively. AECOPD patients 
associated with PA-S were more likely to died at 30-days (Odds Ratio (OR) 
13.53, 95% confidence interval (1.14-69.56, p=0.03) and 90-days (OR 7.09, 
95%IC 1.33-37.89, p=0.02), respectively. 
Conclusions: PA-R affects patients with severe ACOPD and previous use of 
corticosteroids and antibiotics. The presence of PA-S is associated with higher 
mortality. These results may suggest increased virulence in PA-S strains 
causing acute infections. 
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INTRODUCTION 
Acute exacerbations are the most important cause of hospital admission 
and mortality in patients with Chronic Obstructive Pulmonary Disease 
(AECOPD). Approximately 70% of these exacerbations are caused by 
respiratory infections, most of them due to bacteria [1;2]. Pseudomonas 
aeruginosa (PA) accounts for 5-30% of these bacterial exacerbations [1;3-5] 
and its presence was associated with worse clinical outcomes [6;7].   
One of the features of PA is its capacity to generate resistance patterns 
against broad-spectrum antibiotics [8;9]. In recent years, the number of PA 
resistant strains has increased dramatically, limiting the likelihood of selecting 
antibiotics that adequately cover this microorganism [10]. Several studies in 
patients with bacteremia due to PA from different sources showed that 
antimicrobial resistance was related to severe adverse clinical outcomes [11-
14]. A recent retrospective multicenter study of PA nosocomial pneumonia 
demonstrated that the presence of a multi-drug resistant (MDR) strain is 
associated with increased mortality [15]. In COPD, a case-control study showed 
that patients infected with MDR PA had a higher mortality compared to controls 
infected with non-MDR pathogens [16]. However, limited data are available 
regarding the impact of PA resistance patterns on clinical outcomes in 
exacerbations of COPD due to PA [17]. Patients with severe COPD are often 
chronically colonized with PA, where resistant PA may be a marker of 
longstanding PA colonization. During adaptation to chronic infection PA 
downregulates numerous virulence factors including a reduction in 
invasiveness, protease production and secretion of toxins [18]. This may 
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therefore suggest a counter-intuitive conclusion, that the presence of PA-R may 
be a marker of better outcome in AECOPD.  
Therefore, the aim of this study was to characterize the impact of PA 
resistance patterns on clinical outcomes in COPD patients hospitalized due to 
an exacerbation 
 
METHODS 
We conducted a prospective observational study in the Hospital de la 
Santa Creu i Sant Pau, Barcelona from January 1, 2013 to December 31, 2014. 
The study was approved by institutional review board (IIBSP-0921). Written 
consent was waived because of the non-interventional design. 
 
Subjects 
Inclusion criteria were primary diagnosis of exacerbation of COPD and 
PA isolated in sputum culture during first 72 hours of admission. AECOPD was 
defined as an acute event characterized by a worsening of the patient´s 
respiratory symptoms that is beyond normal day-to-day variations and leads to 
a change in medications requiring hospitalization [19]. Diagnosis of COPD was 
confirmed by spirometry with baseline post-bronchodilator FEV1/FVC ratio <0.7 
in all cases. 
Exclusion criteria were airway disease primarily due to other cause 
(bronchiectasis, asthma, pneumonia, Interstitial lung disease) and patients in 
whom active treatment was not considered appropriate at admission (palliative 
care).  
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Data collection 
Demographic data, clinical signs including Anthonisen criteria (ref), 
comorbid conditions, current treatments, smoking history, prior isolation of PA, 
number of hospitalizations for COPD within the last year and use of antibiotics 
and systemic corticosteroids within the last 3 months were recorded in all 
patients.  
Clinical signs, laboratory tests and radiology results were assessed at the 
time of hospital admission. Antimicrobial treatment on admission and changes 
during the hospitalization were also collected.  
 
Microbiological evaluation 
Spontaneous sputum samples were collected in all patients during the 
first 72 hours of admission. Samples were submitted to the laboratory and 
processed immediately. Quality of specimens was determined microscopically 
according to the relative number of polymorphonuclear leukocytes and 
squamous epithelial cells (Bartlett RC, 1974). Samples with a Q-score of 0 or 
less were not processed. Potential pathogens were worked up using the Q234 
score (Sharp S, 2004). All samples were processed, incubated and cultured as 
we previously described (ref). Antimicrobial susceptibility tests were performed 
using disk diffusion or microdilution methods according to guidelines and 
breakpoints established by the Clinical Laboratory Standards Insitute, Wayne, 
PA (CLSI) [20] . Sputum control samples were collected after finished antibiotic 
treatment in those clinically stable patients with sputum production. 
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To be classified as PA-R, the PA isolated in the sputum culture had to be 
non-susceptible to at least one of the following antimicrobial categories: 
antipseudomonal quinolones, antipseudomonal cephalosporins, 
antipseudomonal penicillins plus beta-lactamase inhibitors, antipseudomonal 
carbapenems, aminoglycosides, monobactams and polymixins. To be classified 
as Multi-Drug Resistant (MDR), the PA isolated had to be non-susceptible to 
one or more agents in three or more of the aforementioned antimicrobial 
categories [21]. 
Antimicrobial treatment was considered appropriate if at least one of the 
prescribed antibiotics was active against the identified PA isolated in the sputum 
based on its in vitro susceptibility [22]. 
 
Outcomes 
The primary outcomes were 30-day and 90-day mortality (analysed as 
death from all causes from the first day of admission to completion 90 days of 
follow -up). 
Secondary outcomes were length of hospital stay (LOS), intensive care 
unit  (ICU) admission, need of non-invasive ventilation (NIV), need of 
mechanical ventilation (MV) and persistence of PA in sputum at 90 days. LOS 
was calculated as the date of discharge minus the date of admission. 
Persistence of PA was defined as a new positive PA sputum culture after at 
least 10 days of appropriate antibiotic treatment. 
 
Statistical analysis 
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Univariate statistics were used to test the association of demographic 
and clinical characteristics with the presence of antimicrobial resistance. 
Categorical variables were analyzed using the Chi-square test and the 
continuous variables were analyzed using Student t test. We defined statistical 
significance as a two-tailed p<0.05 
We performed logistic regression analyses using 30-day and 90-day 
mortality as dependent variables and PA-S as independent variable. Variables 
with p<0.1 in the univariate analyses (prior use of systemic steroids and 
antibiotics) were included in the multivariate analyses as potential cofounders. 
We also present a Kaplan-Meier curve representing the survival data. A 
secondary analysis was performed including only patients with PAR (MDR vs. 
not-MDR). All analyses were performed with SPSS 19.0 software program 
(SPSS Inc, Chicago, IL, USA). 
 
RESULTS 
During the study period, 401 patients were hospitalized with a primary 
diagnosis of AECOPD. PA was isolated from sputum samples obtained within 
72 hours of hospitalization in 54 (13%) patients. The majority of the patients 
with AECOPD with PA in the sputum were man (n=48% [88%]), the median age 
(± SD) was 76 (± 7) years old, the median FEV1 was 36 (± 17) % of predicted 
value and 8 (15%) were current smokers. Hypertension (64%) was the most 
common comorbid condition, and bronchiectasis (related to COPD) were 
present in 20% of the patients. Sputum purulence were present in 39 patients 
(72%) and median Anthoniesen criteria (± SD) were 2.2 (±0.5) suggesting an 
acute infectious exacerbation. 9 (16%) of the patients died before 90 days of 
Commented [os5]: James, do you think is it clear? It is important 
to remark that BE were not primary diagnosis... 
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follow-up. In all cases, respiratory failure was considered the cause of death. 
Most of the patients with confirmed PA-AECOPD had resistance to at least one 
antimicrobial category (PA-R, n=36 patients [66%]) and only one third (n=18 
[33%]) of the patients had a sensitive PA (PA-S). 
 
1) Patient characteristics  
Table 1 shows the characteristics of the subjects, grouped by whether 
they had PA-R or PA-S in the sputum. There were no statistical significant 
differences in gender, age, smoking status, lung function tests, pre-existing 
comorbid conditions, prior hospital, ICU and health-care admissions, clinical 
signs, laboratory tests and prior medications used among groups. However, PA-
R patients were more likely to received prior systemic corticosteroids (77% vs. 
44%, p=0.03) and prior antibiotics (77% vs 33%, p=0.01). AECOPD patients 
with evidence of prior (12 months) PA sputum isolation had a trend towards 
higher rates of PA-R compared to PA-S group (50% vs 22%, p=0.05). 
Antibiotic treatment was similar in both groups (p=0.2). Cefepime (32%) 
and levofloxacin (30%) were the most common antibiotic used. Median days 
(±SD) were 12.5 ± 2.4 in the PA-R group and 13.7 ± 2.1 in the PA-S group 
(p=0.08). Initial antibiotic empiric treatment was appropriate in 12/18 (66%) of 
patients in the PAS group and 23/36 (63%) patients (p=0.7). Based on the 
results of antimicrobial susceptibility tests, antibiotic treatment was changed in 6 
patients (33%) in the PA-S group and in 13 patients (36%) in the PA-R group 
and (p=0.8).  Monotherapy was used in 27 patients (75%) with PA-R and in 16 
patients (88%) with PA-S (p=0.2). 
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2) Outcomes. 
Table 2 shows clinical outcomes evaluated according PA antimicrobial 
resistance patterns. Patients with PA-S had higher 30-day (Odds Ratio (OR) 
13.53, 95% confidence interval (95CI) 1.14-69.56, p= 0.03) and 90-day mortality 
(OR 7.09, 95%IC 1.33-37.89, p= 0.02) in the multivariate analyses. Figure 1 
shows the survival curves. Patients with PA-S had a longer hospital LOS (19.3 
vs. 12.9 days, p=0.01). There were no differences on the rate of ICU admission 
and need for non-invasive or invasive mechanical ventilation.  
 However, in those patients who had received appropriate antibiotic 
treatment and control sputum was performed (n=38), persistence of PA was 
higher in the PA-R group compared to the PA-S group (50 vs. 83%, p=0.04).  
 
3) Subgroup analysis 
In order to assess the influence of MDR resistance pattern, we 
performed an additional analysis including only patients with PA-R (n=36). Of 
them, 17 patients (47%) had PA strains resistant to less than 3 different 
antibiotics classes (no MDR) and 19 (53%) had PA strains resistant to 3 or 
more different antibiotics classes (MDR).  
There were no differences in the baseline characteristics among PA-R 
not-MDR and MDR, except that not-MDR had a higher rate of prior malignancy 
(47% vs 15%, p= 0.04) (Table 3). In addition, there were no statistical 
significant differences in the primary and secondary clinical outcomes among 
patients stratified according to the MDR status (Table 4). Persistence of PA was 
higher in the MDR group (87% vs 75%), although differences were not 
statistically significant (p=0.7). 
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DISCUSSION 
The main findings of our study are that COPD patients hospitalized with an 
exacerbation due to PA-S have higher 30-day and 90-day mortality compared to 
those with PA-R. However, the persistence of PA in the sputum after a proper 
antibiotic treatment was higher in those patients with PA-R. This suggests an 
important difference in the virulence characteristics of sensitive and resistant 
isolates in this population.  
Infection with PA plays an important role in the course of chronic lung 
diseases. The presence of PA is considered crucial and has been associated 
with increased mortality in Cystic Fibrosis and bronchiectasis [23;24]. In COPD, 
some studies have demonstrated a high incidence during acute exacerbations 
[25;26] and have related the presence of PA in the sputum to higher mortality 
[6;27]. These findings are concordant with our cohort, where the prevalence of 
PA was 13% of hospitalized COPD patients and mortality among patients with 
PA was very high, reaching 18% at 90 days.  
An important clinical concern related to PA is its fast acquisition of 
resistance to one or various antimicrobial agents [9;28]. The prevalence of PA-
R is increasing, especially in nosocomial infections [8;29]. In our study, the 
prevalence of PA-R was around 13% of the whole cohort of COPD admitted 
patients and 66% of patients with PA in the sputum, which is higher than 
previous studies [16;25]. The administrations of corticosteroids and antibiotics in 
the previous 3 months were factors associated with the presence of PA-R. Prior 
antibiotic therapy, oral steroid use, prior hospitalization and FEV1 less than 35% 
have been related to the presence of PA in a culture of sputum at the time of 
exacerbation [25;30], but no to the presence of PA-R. This finding may have 
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important consequences in order to determine PA resistance patterns in these 
patients. 
Recent studies in hospital-acquired infections have detected worse 
outcomes among those patients suffering PA-R. Micek et al demonstrated that 
in patients with PA nosocomial pneumonia, the presence of a MDR strain was 
associated with inappropriate initial antibiotic treatment and increased in-
hospital mortality [15]. Different studies in hospitalized patients with PA 
bacteremia, most of them due to pneumonia [11;14], showed increased LOS 
and mortality among those with MDR PA isolation. In COPD patients, Montero 
et al [16] demonstrated in a case-control study that exacerbated COPD patients 
with MDR PA in the sputum had a higher long-term mortality compared to 
COPD patients with sensitive microorganisms isolated in the sputum. PA may 
colonize the respiratory tract of people with COPD, especially in those with 
severe disease [4;31]. Murphy et al [5] reported two distinct patterns of carriage 
of PA among COPD patients in a large prospective cohort; a short-term 
infection followed by clearance and a long-term persistence mostly due to 
mucoid strains. In addition, these authors showed a strong association between 
acquisition of a new strain of PA and the presence of an acute exacerbation of 
COPD. These findings could have an important significance and may potentially 
explain why our patients with PA-S had higher rates of mortality, but were less 
likely to persist in the sputum of appropriately treated patients. In addition, it 
also suggests that patients with PA-R may be more likely to have PA 
colonization for long periods of time, modulating the immune response and 
protecting them for poor clinical outcomes, despite the difficulties to fully 
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eradicate the bacteria by the use of appropriate antimicrobial agents. Further 
studies are needed to investigate this important clinical observation. 
The key determinants of outcome in PA infection are likely to be the 
availability of effective antimicrobial therapy, and the virulence of the infecting 
microorganism. In the context of MDR PA, with the administration of 
inappropriate antibiotic therapy we may expect higher mortality. In this study, 
however, we hypothesized that if appropriate antibiotic therapy was used, 
patients with PA-R would have better outcomes because of the downregulation 
of virulence factors associated with chronic infection and the acquisition of 
antibiotic resistance. It is well described that acquisition of antibiotic resistance 
genes typically confers a fitness cost on bacteria in terms of reduced virulence 
[32]. In addition, antibiotic resistant is often associated with chronic infection, 
and it has been shown across multiple studies in cystic fibrosis that adaptation 
to chronic infection in the airway involves multiple gene alterations to reduce 
antigenicity, invasiveness and secretion of toxins. Indeed the “hallmark” of 
chronic PA infection, the formation of biofilms is intrinsically linked to the 
development of antibiotic resistance [33]. 
In this study, we found that the presence of PA-R was associated with lower 
30- and 90-day mortality, where no differences regarding proper initial antibiotic 
therapy among groups were found. Furthermore, patients with PA-R had a trend 
of a higher rate of prior PA isolation and a higher persistence of PA after 
antibiotic treatment. These findings suggested that PA-R chronically colonized 
patients with severe COPD. The implications of these findings are therefore 
important for our understanding of PA infections in COPD. It appears that in 
contrast to common belief that PA-R is associated with higher virulence and 
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mortality, if patients are treated with appropriate antimicrobial therapy the 
reverse is true, and lower virulence in chronic strains results in improved patient 
outcomes. Limits among colonization and infection are still not clear and 
requires further studies to better elucidate. 
Our study has several limitations. First, because the data were collected 
from a single academic center in Spain, the results might not be generalizable 
to other COPD patients admitted to other types of hospitals and other countries. 
Second, although it is larger that other studies that evaluated clinical outcomes 
of PA in exacerbated COPD patients [16;25-27], our sample size is small, 
especially for comparing MDR and not-MDR PAR. Third, we did not collected 
data on patients without PA in their sputum and it is not possible to compare 
risk factors and outcomes among patients with and without PA in their sputum. 
Fourth, the study was performed exclusively in hospitalized COPD patients, 
where PA isolation is more frequent than outpatients with COPD [34]. Fifth, 
although all patients included in the study had an acute episode, the isolation of 
PA in spontaneous sputum can either represent upper airway colonization or 
lower respiratory tract infection, which it is not possible to differentiate in these 
patients. And finally, it is not possible to exclude the role of bronchiectasis as a 
cofounder in the whole cohort. 
 In conclusion, we suggest that hospitalized COPD patients with an acute 
exacerbation and the isolation of PA in the sputum during the first 72 hours of 
admission have different clinical outcomes depending PA antimicrobial resistant 
patterns. AECOPD patients with PA-S have higher rates of short-term mortality 
compared to patients with PA-R, but lower rates of PA sputum persistence in 
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spite of an appropriate antimicrobial treatment. Additional studies are needed to 
understand the underlying mechanisms that are responsible for these findings. 
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FIGURE LEGENDS 
 
Figure 1.- Kaplan-Meier survival curves according to the presence of Resistant 
PA (PAR) vs Sensitive PA (PAS). 
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Table 1.- Patient demographics, clinical characteristics, comorbid conditions 
and prior treatments among COPD patients with PAS and PAR in sputum. 
Variables 
 
PA-S  
(n=18) 
PA-R 
 (n=36) 
P value 
Age, years 79 (SD 8.1) 76 (SD 7,2) 0.3 
Male gender  16 (88%) 32 (88%) 0.9 
BMI (kg/m2) 27.7 (SD 4.2) 25.4 (SD 5) 0.6 
Comorbid conditions 
Current smoker 4 (22%) 4 (11%) 0.2 
Current alcohol user 6 (33%) 7 (19%) 0.2 
Ischemic heart disease 4 (22%) 10 (27%) 0.6 
Prior malignancy 6 (33%) 11 (30%) 0.8 
Chronic kidney disease 2 (11%) 6 (16%) 0.5 
Diabetes mellitus 2 (11%) 10 (27%) 0.1 
Hypertension 15 (83%) 20 (55%) 0.1 
Stroke 2 (11%) 2 (5%) 0.4 
Bronchiectasis 2 (11%) 9 (25%) 0.2 
Functional status 
FEV1 (%) 42 (SD 15) 33 (SD17) 0.6 
FVC (%) 62.5 (SD 
15,949) 
65,88 (SD 
14,088) 
0.4 
Oxygen home treatment  12 (66%) 23 (63%) 0.8 
Hospital admissions the 
previous year 
2.3 (SD 2.2) 2.8 (SD 2.0) 0.5 
Current respiratory treatment 
ICS use 14 (77%) 31 (86.1%) 0.4 
LABA use 16 (88%) 35 (97.2%) 0.2 
LAMA use 17 (94.4%) 34 (94.4%) 0.9 
Roflumilast use 2 (11%) 6 (16%) 0.5 
Chronic macrolide 
treatment 
2 (11%) 5 (13%) 0.7 
Previous treatment (last 3 months) 
 19 
SCS  8 (44%) 28 (77%) 0.03 
Antibiotics 7 (38%) 28 (77%) 0.01 
Antibiotics preceding 
admission 
2(11%) 4(11%) 1.0 
Clinical signs 
Fever (≥38º C) 2 (11%) 6 (16%) 0.5 
Temperature 36.2 (SD 0.9) 36.2 (SD 0.8) 0.3 
Sputum purulence 15 (83%) 24 (67%) 0.3 
Anthonisen Criteria  2.44 (SD 0.6) 2.11 (SD 0.4) 0.2 
Laboratory tests 
Leukocytes (U/mL) 14360 (SD 
13977) 
12698 (SD 6941) 0.6 
pO2 (mmHg) 55 (SD 14) 63 (SD15) 0.9 
pO2/FiO2 231.1 (SD 54.3) 242.5 (SD 48.5) 0.1 
pCO2 (mmHg) 54 (SD 16) 49 (SD 12) 0.1 
Previous admission    
≥ 2 Hospital 
admission/year 
7 (38%) 11 (30%) 0.6 
Healthcare 
admission/previous year 
2(11%) 5 (14%) 0.7 
ICU admission/previous 
year 
0(0%) 1 (2.8%) 0.4 
Number  of Hospital 
admissions/previous year 
2.3 (SD 2.2) 2.8 (SD 2.0) 0.5 
Number of Healthcare 
admissions/previous year 
0.11 (SD 0.3) 0.19 (SD 0.5) 0.5 
 
Data are presented as n (%) unless otherwise indicated. 
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; BMI: body 
mass index; ICS; inhaled corticosteroids, LABA: long acting beta-agonist, 
LAMA: long acting muscarinic antagonist. SCS: Systemic Corticosteroids 
ICU; Intensive Care Unit 
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Table 2.- Outcomes according PA resistance patterns in COPD exacerbations. 
 
 PA S 
(n=18) 
PA R 
(n=36) 
P value 
30-day mortality 4 (22%) 1 (2.8%) 0.03 
90-day mortality 6 (33%) 3 (8.3%) 0.04 
Hospital LOS 19.3 (SD28.6) 12.9 (SD7.4) 0.01 
Intensive care Unit 
admission 
3 (16%) 2 (5.6%) 0.1 
NIV 5 (27%) 7 (19%) 0.5  
MV 3 (16%)  1 (2.7%)  0.06 
Persistence 90-days 4/8 (50%) 25/30 (83%)  0.01 
 
Data are presented as n (%) unless otherwise indicated. 
LOS: Length-of Stay; NIV; Non-invasive ventilation; MV: Mechanical Ventilation 
 
 
 
 
 
 
 
 
 
 
 21 
Table 3. Patient demographics, clinical characteristics, comorbid conditions and 
prior treatments among COPD patients with PAR not-MDR and MDR in sputum. 
 
Variables Not-MDR 
(n=17) 
MDR 
(n=19) 
p value 
Age, years 76.2 (SD 8.3) 77.3 (SD 6.3) 0.3 
Sex (male)  15 (88%) 17 (89%) 0.9 
BMI (kg/m2) 25.4 (SD 5.9) 25.4 (SD 4.2) 0.3 
Comorbid conditions 
Current smoker 2 (11.8%) 2 (10.5%) 0.9 
Current alcohol user 2 (12.5%) 5 (26.3%) 0.3 
Ischemic heart disease 4 (23.5%) 6 (31.6%) 0.51 
Prior malignancy 8 (47.1%) 3 (15.8%) 0.04 
Chronic kidney disease 3 (17.6%) 3 (15.8%) 0.08 
Diabetes mellitus 6 (35.3%) 4 (21.1%) 0.3 
Hypertension 8 (47%) 12 (63.2%) 0.4 
Stroke 1 (5.9%) 1 (5.3%) 0.9 
Bronchiectasis 6 (35.3%) 3 (16%) 0.3 
Functional status 
FEV1 (%) 34.8 (SD 18.7) 32.5 (SD 16.0) 0.5 
FVC (%) 62 (SD 14.9) 63 (SD 17.2) 0.3 
Oxygen home treatment  9 (52.9%) 14 (73.7%) 0.1 
Current respiratory treatment 
ICS use 14 (82%) 17 (89%) 0.5 
LABA use 17 (100%) 18 (94%) 0.3 
LAMA use 16 (94%) 18 (94%) 0.9 
Roflumilast use 3 (17.6%) 3 (15.8%) 0.8 
Chronic macrolide 
treatment 
2 (11.8%) 3 (15.8%) 0.7 
Previous treatment (last 3 months) 
SCS  13 (76.5%) 15 (78.9%) 0.8 
Antibiotics 13 (76.5%) 15 (78.9%) 0.8 
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Clinical signs 
Fever (≥38º C) 1 (5.9%) 5 (26.3%) 0.1 
Temperature 36,282 (SD 
0.77) 
36,621 (SD 1.03) 0.2 
Laboratory tests 
Leukocytes (U/mL) 13011 (SD 
7420) 
12418 (SD 6676) 0.5 
pO2 (mmHg) 64.2 (SD 12.4) 62.6 (SD 18.36) 0.2 
pO2/FiO2 256.7 (SD 58.6) 230.9 (SD 36.4) 0.3 
pCO2 (mmHg) 50.4 (SD 11.4) 49 (SD 12.9) 0.8 
Previous admission    
≥ 2 Hospital 
admission/year 
5 (38.5%) 6 (35.3) 0.8 
Number of Hospital 
admissions/ previous 
year 
3 (SD 2.7) 2.6 (SD 1.2) 0.2 
 
Data are presented as n (%) unless otherwise indicated. 
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; BMI: body 
mass index; ICS; inhaled corticosteroids, LABA: long acting beta-agonist, 
LAMA: long acting muscarinic antagonist. SCS: Systemic Corticosteroids 
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Table 4. Outcomes according the presence of multi-drug resistance (MDR) in 
COPD patients with PAR. 
 
 Not-MDR MDR p value 
30-day mortality 1 (5.9%) 0% 0.3 
90-day mortality 3 (17.6%) 0% 0.05 
Hospital LOS 13.1 (SD 6.8) 12.8 (SD 8) 0.6 
Intensive care Unit 
admission 
1 (5.9%) 1 (5.3%) 0.9 
NIV 5 (31.3%) 2 (10.5%) 0.1 
MV 0% 1 (5.3%) 0.3 
Persistence 90-days 11/14 (75%) 14/16 (87%) 0.7 
 
Data are presented as n (%) unless otherwise indicated. 
LOS: Length-of Stay; NIV; Non-invasive mechanical ventilation; MV: Mechanical 
Ventilation 
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